NDC product
CEO-TWO
NDC 0283-1023 · Beutlich Pharmaceuticals, LLC
Key facts
| Product NDC | 0283-1023 |
|---|---|
| Proprietary name | CEO-TWO |
| Nonproprietary name | Laxative |
| Substances | POTASSIUM BITARTRATE, SODIUM BICARBONATE |
| Dosage form | SUPPOSITORY |
| Route | RECTAL |
| Labeler | Beutlich Pharmaceuticals, LLC |
| Product type | HUMAN OTC DRUG |
| Marketing category | OTC MONOGRAPH DRUG |
| Application number | M007 |
| Pharmacologic classes | Alkalinizing Activity [MoA], Increased Large Intestinal Motility [PE], Inhibition Large Intestine Fluid/Electrolyte Absorption [PE], Osmotic Activity [MoA], Osmotic Laxative [EPC], Potassium Compounds [CS] and 1 more |
| Marketing start | Oct 15, 2023 |
| Listing certified through | Dec 31, 2026 |
At a glance
- 1–9 Package NDCs
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About National Drug Codes (NDC)
The National Drug Code (NDC) is the FDA's product identifier for drugs; the product NDC identifies the labeler and product, and each package adds a package code.
Source: U.S. Food and Drug Administration (FDA), National Drug Code Directory · Source date: